June 27, 2022

Onconova Therapeutics (NASDAQ: ONTX) was reduced by Zacks Investment Research  from a “get” score to a “hold” ranking in a research note issued to financiers on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It concentrates on discovering and also establishing small particle medicine candidates to deal with cancer. The Business‘s products under different stages of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of various other equities research experts likewise lately talked about the firm. Noble Financial reissued a “get” ranking and issued a $11.00 cost objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “acquire” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day moving average cost of $2.90 as well as a two-hundred day relocating typical price of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) profits per share for the quarter, covering analysts’ consensus price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% as well as a negative web margin of 8,294.27%. The firm had revenue of $0.06 million during the quarter, contrasted to the agreement price quote of $0.06 million. During the same quarter in the prior year, the firm uploaded ($ 0.45) EPS. As a group, research analysts forecast that Onconova Therapeutics will certainly upload -1.18 EPS for the existing year.

A variety of hedge funds have recently bought and sold shares of ONTX. GSA Resources Partners LLP got a brand-new position in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Capital Monitoring LP acquired a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC purchased a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC got a new setting in shares of Onconova Therapeutics in the third quarter worth $493,000. Finally, Dimensional Fund Advisors LP purchased a new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as other institutional financiers own 13.36% of the company’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the recognition and development of oncology therapeutics. It focuses on uncovering and developing little molecule medicine prospects to deal with cancer. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Obtain a cost-free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

To find out more regarding research offerings from Zacks Investment Research, check out Zacks.com.

This instant news alert was generated by narrative scientific research technology and financial data from Market in order to supply viewers with the fastest and most accurate coverage. This story was evaluated by Market’s editorial team before magazine. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS RIGHT NOW?

Prior to you take into consideration Onconova Therapeutics, you’ll intend to hear this.

Market keeps an eye on Wall Street’s premier and also finest doing research experts as well as the stocks they advise to their customers every day. Market has actually recognized the five stocks that cover experts are quietly murmuring to their clients to get now prior to the broader market catches on … as well as Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics presently has a “Buy” score among analysts, premier experts think these five stocks are much better buys.